LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Back to previous search Search history
Advanced search

Your last searches

  1. TI=Autologous hematopoietic transplantation following COVID 19 infection
  2. TI=Effects of COVID 19 on Pregnant women: Evidence based review

Search results

Result 1 - 6 of total 6

Search options

  1. Article: Autologous hematopoietic transplantation following COVID-19 infection.

    Brzycki, Marthilde / Richard, Robert / Burwick, Nicholas / Graf, Solomon / O'Brien, Craig / Wu, Daniel / Chauncey, Thomas R

    Clinical case reports

    2021  Volume 9, Issue 3, Page(s) 1167–1170

    Abstract: Autologous hematopoietic cell transplantation following induction therapy is standard of care ...

    Abstract Autologous hematopoietic cell transplantation following induction therapy is standard of care for most patients with newly diagnosed multiple myeloma (
    Language English
    Publishing date 2021-01-03
    Publishing country England
    Document type Case Reports
    ZDB-ID 2740234-4
    ISSN 2050-0904
    ISSN 2050-0904
    DOI 10.1002/ccr3.3712
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Prolonged SARS-CoV-2 infection during autologous hematopoietic stem cell transplantation from Hodgkin's lymphoma: a case report.

    Abakarim, Ouadii / Lahlimi, Fatima Ezzahra / Maghnouj, Oumaima / Tazi, Illias

    The Pan African medical journal

    2023  Volume 44, Page(s) 133

    Abstract: Autologous hematopoietic stem cell transplantation (HSCT) for relapsed Hodgkin's lymphoma increases ... virulence of severe COVID-19. We report a case of a young man with Hodgkin's lymphoma who received ... reaction (PCR) during the early phase of aplasia with persistence of COVID-19 beyond 30 days with favorable ...

    Abstract Autologous hematopoietic stem cell transplantation (HSCT) for relapsed Hodgkin's lymphoma increases the risk of infection by using intensive chemotherapy. This risk is obviously ongoing given the increased virulence of severe COVID-19. We report a case of a young man with Hodgkin's lymphoma who received conditioning chemotherapy followed by autologous HSCT and tested positive for SARS-CoV-2 by polymerase chain reaction (PCR) during the early phase of aplasia with persistence of COVID-19 beyond 30 days with favorable follow-up and clinical improvement on treatment. For this type of patient with hematologic malignancy, viral infection can be fatal and strict medical precautions with isolation rules must be maintained, especially for SARS-CoV-2.
    MeSH term(s) Male ; Humans ; Hodgkin Disease/therapy ; Hodgkin Disease/pathology ; COVID-19/therapy ; SARS-CoV-2 ; Hematopoietic Stem Cell Transplantation ; Transplantation, Autologous
    Language English
    Publishing date 2023-03-16
    Publishing country Uganda
    Document type Case Reports
    ZDB-ID 2514347-5
    ISSN 1937-8688 ; 1937-8688
    ISSN (online) 1937-8688
    ISSN 1937-8688
    DOI 10.11604/pamj.2023.44.133.36277
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Comparison of two autologous hematopoietic stem cell mobilization strategies in patients with multiple myeloma: CE plus G-CSF versus G-CSF only: A single-center retrospective analysis.

    Dill, Veronika / Blüm, Philipp / Lindemann, Anja / Biederstädt, Alexander / Högner, Marion / Götze, Katharina S / Bassermann, Florian / Hildebrandt, Martin

    Transfusion

    2024  Volume 64, Issue 5, Page(s) 871–880

    Abstract: ... followed by autologous hematopoietic stem cell transplantation (ASCT) remains an essential therapeutic ... to primarily use G-CSF only mobilization during the COVID-19 pandemic to minimize the patients' risk ... to collect the target dose of hematopoietic stem cells in the majority of our patients. CE mobilization ...

    Abstract Background: Despite recent advances in the treatment of multiple myeloma, high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (ASCT) remains an essential therapeutic keystone. As for the stem cell mobilization procedure, different regimens have been established, usually consisting of a cycle of chemotherapy followed by application of granulocyte-colony stimulating factor (G-CSF), although febrile neutropenia is a common complication. Following national guidelines, our institution decided to primarily use G-CSF only mobilization during the COVID-19 pandemic to minimize the patients' risk of infection and to reduce the burden on the health system.
    Study design and methods: In this retrospective single-center analysis, the efficacy and safety of G-CSF only mobilization was evaluated and compared to a historic control cohort undergoing chemotherapy-based mobilization by cyclophosphamide and etoposide (CE) plus G-CSF.
    Results: Although G-CSF only was associated with a higher need for plerixafor administration (p < .0001) and a higher number of apheresis sessions per patient (p = .0002), we were able to collect the target dose of hematopoietic stem cells in the majority of our patients. CE mobilization achieved higher hematopoietic stem cell yields (p = .0015) and shorter apheresis sessions (p < .0001) yet was accompanied by an increased risk of febrile neutropenia (p < .0001). There was no difference in engraftment after ASCT.
    Discussion: G-CSF only mobilization is a useful option in selected patients with comorbidities and an increased risk of serious infections, especially in the wintertime or in future pandemics.
    MeSH term(s) Humans ; Hematopoietic Stem Cell Mobilization/methods ; Multiple Myeloma/therapy ; Retrospective Studies ; Granulocyte Colony-Stimulating Factor/administration & dosage ; Granulocyte Colony-Stimulating Factor/therapeutic use ; Middle Aged ; Male ; Female ; Cyclophosphamide/therapeutic use ; Cyclophosphamide/administration & dosage ; Transplantation, Autologous ; Aged ; Etoposide/therapeutic use ; Etoposide/administration & dosage ; Hematopoietic Stem Cell Transplantation/methods ; Benzylamines ; COVID-19 ; Adult ; Cyclams/therapeutic use ; Cyclams/pharmacology ; SARS-CoV-2 ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/adverse effects
    Chemical Substances Granulocyte Colony-Stimulating Factor (143011-72-7) ; Cyclophosphamide (8N3DW7272P) ; Etoposide (6PLQ3CP4P3) ; Benzylamines ; plerixafor (S915P5499N) ; Cyclams
    Language English
    Publishing date 2024-04-10
    Publishing country United States
    Document type Journal Article ; Comparative Study
    ZDB-ID 208417-x
    ISSN 1537-2995 ; 0041-1132
    ISSN (online) 1537-2995
    ISSN 0041-1132
    DOI 10.1111/trf.17829
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 284: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Extracorporeal membrane oxygenation (ECMO) during aplasia: A bridge towards myopericarditis recovery after autologous hematopoietic stem cell transplant for systemic sclerosis and recent Coronarovirus disease (COVID-19) vaccination.

    Cacciatore, Carlotta / Baudet, Mathilde / Jean, Estelle / Presente, Simona / Para, Marylou / Sonneville, Romain / Arangalage, Dimitri / Ait Abdallah, Nassim / Sicre de Fontbrune, Flore / Prata, Pedro Henrique / Crichi, Benjamin / Hervier, Baptiste / Parquet, Nathalie / Soulat, Gilles / Mousseaux, Elie / Burt, Richard K / Farge, Dominique

    Current research in translational medicine

    2024  Volume 72, Issue 3, Page(s) 103449

    Abstract: ... progressive diffuse SSc (dSSc), autologous hematopoietic stem cell transplantation (aHSCT) improves survival ... autoimmune activation with disease flair per se. In the COVID-19 pandemic times, acute myocarditis due ... to recent viral infection or mRNA vaccine per se, must also be considered. ...

    Abstract Systemic sclerosis (SSc) is a rare autoimmune disease (AD), characterised by early diffuse vasculopathy, activation of the immune response and progressive skin and internal organ fibrosis. In severe progressive diffuse SSc (dSSc), autologous hematopoietic stem cell transplantation (aHSCT) improves survival, despite its own risk of complications and transplant related mortality (TRM). We present herein the case of a dSSc patient undergoing aHSCT with low dose cyclophosphamide conditioning and sudden acute myopericarditis and cardiogenic shock, four weeks after a second mRNA SARS-CoV-2 vaccine (Pfizer) injection. Four days of extracorporeal membrane oxygenation (ECMO) support during the aplasia period, allowed to observe full cardiac function recovery and progressive SSc rehabilitation with sustained disease response at 30 months follow-up. This report illustrates, for the first time to our knowledge, that ECMO can be indicated despite aplasia during aHSCT and successfully used as a bridge towards heart function recovery in highly selected and fragile AD patients. We review the factors that may contribute to endothelial and myocardial stunning and acute reversible cardiac failure in SSc and aggravate intrinsic endothelial injury during the aHSCT procedure. These classically include: cyclophosphamide drug toxicity, viral infections and autoimmune activation with disease flair per se. In the COVID-19 pandemic times, acute myocarditis due to recent viral infection or mRNA vaccine per se, must also be considered.
    Language English
    Publishing date 2024-04-09
    Publishing country France
    Document type Journal Article
    ISSN 2452-3186
    ISSN (online) 2452-3186
    DOI 10.1016/j.retram.2024.103449
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  5. Article: Evaluation of Safety and Immunogenicity of a Recombinant Receptor-Binding Domain (RBD)-Tetanus Toxoid (TT) Conjugated SARS-CoV-2 Vaccine (PastoCovac) in Recipients of Autologous Hematopoietic Stem Cell Transplantation Compared to the Healthy Controls; A Prospective, Open-Label Clinical Trial.

    Barkhordar, Maryam / Ahmadvand, Mohammad / Sharifi Aliabadi, Leyla / Noorani, Seied Saeid / Bagheri Amiri, Fahimeh / Janbabai, Ghasem / Sorouri, Rahim / Asadi Milani, Mona / Vaezi, Mohammad

    Vaccines

    2023  Volume 11, Issue 1

    Abstract: ... of obtaining COVID-19 infection before transplantation [OR: 6.24 (95% CI: 1.17−33.15); p = 0.03] remained ... we found that the immunogenicity of the COVID-19 vaccine shortly after transplantation could be influenced ... by pre-transplant COVID-19 vaccination. Interpretation: The RBD-TT conjugated SARS-CoV-2 vaccine was safe ...

    Abstract Background: The urgent need for prompt SARS-CoV-2 immunization of hematopoietic stem cell transplant (HSCT) recipients in an endemic area raises many challenges regarding selecting a vaccine platform appropriate for HSCT recipients being economical for widespread use in developing countries. Methods: The trial is a prospective, single-group, open-label study to investigate the safety and serologic response of two doses of the recombinant receptor-binding domain (RBD)-Tetanus Toxoid (TT) conjugated SARS-CoV-2 vaccine (PastoCovac) early after autologous (auto) HSCT. For this reason, a total of 38 patients who completed the two-dose SARS-CoV-2 RBD-based vaccine between three to nine months after auto-HSCT and had an available anti-spike serologic test at three predefined time points of baseline and after the first and second doses and 50 healthy control individuals were included in the analysis. The primary outcome was defined as an increase in IgG Immune status ratio (ISR) to the cut-off value for the positive result (≥1.1) in the semiquantitative test. Findings: The median time between auto-HSCT and vaccination was 127 days. No participant reported any significant adverse effects (Grade 3). Pain at the injection site was the most common adverse event. The ISR increased significantly (p < 0.001) during the three-time point sampling for both patients and healthy control groups. In patients, the mean ISR increased from 1.39 (95% CI: 1.13−1.65) at baseline to 2.48 (1.93−3.03) and 3.73 (3.13−4.38) following the first and second dosages, respectively. In multivariate analysis, the higher count of lymphocytes [OR: 8.57 (95% CI: 1.51−48.75); p = 0.02] and history of obtaining COVID-19 infection before transplantation [OR: 6.24 (95% CI: 1.17−33.15); p = 0.03] remained the predictors of the stronger immune response following two doses of the RBD-TT conjugated vaccine. Moreover, we found that the immunogenicity of the COVID-19 vaccine shortly after transplantation could be influenced by pre-transplant COVID-19 vaccination. Interpretation: The RBD-TT conjugated SARS-CoV-2 vaccine was safe, highly immunogenic, and affordable early after autologous transplants. Funding: This work was mainly financed by the Hematology-Oncology-Stem Cell Transplantation Research Center (HORCSCT) of Tehran University and the Pasteur Institute of Iran.
    Language English
    Publishing date 2023-01-03
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2703319-3
    ISSN 2076-393X
    ISSN 2076-393X
    DOI 10.3390/vaccines11010117
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Successful second outpatient autologous hematopoietic cell transplant for relapsed POEMS syndrome in a patient with coexisting HIV, HBV and syphilis infections during the COVID-19 pandemic.

    Hernández-Coronado, Marcela / Jaime-Pérez, José Carlos / Villarreal-Martínez, Alejandra / Ocampo-Candiani, Jorge / Gómez-Almaguer, David

    Transplant immunology

    2021  Volume 67, Page(s) 101412

    Abstract: ... treated with a second ambulatory autologous hematopoietic-cell transplantation (AHCT) after a daratumumab ... desensitization protocol performed during the coronavirus disease (COVID-19) pandemic in a patient with coexisting ... cryopreserved autograft infusion were carried out in an outpatient basis. Following second AHCT, the patient ...

    Abstract Polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome is a multisystem autoinflammatory disease due to an underlying plasma cell disorder that lacks a standard treatment strategy because of its rarity. We report a case of relapsed POEMS syndrome successfully treated with a second ambulatory autologous hematopoietic-cell transplantation (AHCT) after a daratumumab desensitization protocol performed during the coronavirus disease (COVID-19) pandemic in a patient with coexisting human immunodeficiency virus (HIV), hepatitis B virus (HBV) and syphilis infections. He is a 37-year old Latin-American male who had been treated with radiation, CyBorD regimen, AHCT and bortezomib therapy before being referred to our service. It was decided to administer daratumumab therapy and subsequently perform the transplant. Placement of central venous access, fluid infusion, conditioning regimen with melphalan and previously cryopreserved autograft infusion were carried out in an outpatient basis. Following second AHCT, the patient demonstrated clinical, VEGF, hematological response and remains SARS-CoV-2 infection-free and in POEMS remission with excellent quality-of-life at last follow up (6 months). We evidenced that thanks to an outpatient transplant program, the best therapeutic modalities can be offered to patients with hematologic malignancies in the context of present or future pandemics. Finally, high-complexity patients with HIV infection should have access to the same treatment strategies as non-infected patients. A second AHCT in the outpatient setting is feasible, safe and highly effective to treat patients with relapsed POEMS syndrome.
    MeSH term(s) Adult ; Antibodies, Monoclonal/therapeutic use ; Antineoplastic Agents/therapeutic use ; Bortezomib/therapeutic use ; COVID-19/epidemiology ; HIV Infections/complications ; Hematopoietic Stem Cell Transplantation ; Hepatitis B, Chronic/complications ; Humans ; Immunocompromised Host ; Male ; POEMS Syndrome/surgery ; SARS-CoV-2 ; Syphilis/complications ; Transplantation, Autologous ; Treatment Outcome
    Chemical Substances Antibodies, Monoclonal ; Antineoplastic Agents ; daratumumab (4Z63YK6E0E) ; Bortezomib (69G8BD63PP)
    Language English
    Publishing date 2021-05-19
    Publishing country Netherlands
    Document type Case Reports ; Journal Article
    ZDB-ID 1160846-8
    ISSN 1878-5492 ; 0966-3274
    ISSN (online) 1878-5492
    ISSN 0966-3274
    DOI 10.1016/j.trim.2021.101412
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3784: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top